
Thermo Fisher posts 10% revenue growth, boosted by Pharma and Biotech recovery and strategic acquisitions.
Thermo Fisher Scientific reported a 10% revenue increase in Q2 2026, driven by 5% organic growth and improved margins. The company’s Pharma and Biotech sectors showed mid-single-digit gains, reflecting a market rebound. Recent acquisitions of Clario ...


